Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Bert O'Malley
Baylor College of Medicine, Department: Pharmacology
Should you be removed from our database? Contact us at [email protected]. Read more below.
Coactigon, Inc.
Salary not from the awardee Institution
The RCOIC reviewed your SFI with Coactigon, Inc., the aims and scope of this funded research, and your role of conducting and managing the research. Coactigon is a BCM start-up company that develops several different SRC3 chemical probes with slight differences. These probes are the only products currently under development.
This project is to discover and research small compounds that are designed to help fight cancers (beginning with breast cancer). The molecules inhibit transcription of the RNA in cells. The company was formed to develop and test these compounds. Research supported by this National Institutes of Health grant involves the development of SRC-3 small molecule inhibitors that are also being developed by Coactigon, Inc. The purposes of the funded research and the purpose of the company have overlap in this area of research being designed, developed, and tested. Since the funded research is to design, develop, and test the same molecules for which the company was founded, and these molecules are used in the treatment of breast cancer, the committee determined that the investigator’s SFI could directly and/or significantly affect the design, conduct, or reporting of the research, and was therefore a FCOI.
Drugging the Undruggable Coactivators using Small Molecule Inhibitors
Breast cancer is the most frequently diagnosed and second most lethal cancer among women in the United States. Drug resistance and tumor metastasis are the major challenges to current breast cancer treatment. In this proposal, we will develop a targeted therapy to reverse drug resistance and reduce metastasis in breast cancer.
Filed on May 10, 2019.
Tell us what you know about Bert O'Malley's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Bert O'Malley”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Bert O'Malley | Baylor College of Medicine | Conflict of Interest | Coactigon, Inc. | Value cannot be readily determined |
| Bert O'Malley | Baylor College of Medicine | Conflict of Interest | Coactigon, Inc. | Value cannot be readily determined |
| Bert O'Malley | Baylor College of Medicine | Conflict of Interest | Coactigon, Inc. | $0 - $4,999 |
| Bert O'Malley | Baylor College of Medicine | Conflict of Interest | Coactigon, Inc. | $0 - $4,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.